TheraRadar
← Back
Data updated: Sep 20, 2026

Apotex

Generics

Apotex is a generic drug manufacturer focused on Cardiovascular, Neurology, Oncology. Key products include IVRA.

1964
Since
287
Drugs
-
Trials
4
New Drugs (2yr)
Modality:
7 Small Molecules

Apotex's Therapeutic Areas

Apotex's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 7 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 31%
22 drugs
Neurology 24%
17 drugs
Oncology 17%
12 drugs
Infectious Disease 17%
12 drugs
Immunology 10%
7 drugs

Apotex Pipeline Snapshot

Active clinical trials for Apotex across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM leads revenue
  • 5 key drugs tracked

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling